Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma.
Chugh S, Tien JC, Hon J, Kenum C, Mannan R, Cheng Y, Li CC, Taher ZI, Delekta AD, Bawa PS, Apel IJ, Miner SJ, Cao X, Mehra R, Dhanasekaran SM, Qiao Y, Mody R, Chinnaiyan AM.
Chugh S, et al. Among authors: cheng y.
Neoplasia. 2025 Feb;60:100964. doi: 10.1016/j.neo.2024.100964. Epub 2024 Jan 6.
Neoplasia. 2025.
PMID: 39900433
Free article.